Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study

Purpose

Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study.

Primary Outcome Measures:

1. Recurrent venous thromboembolism [ Time Frame: 6 months ]

Primary efficacy outcome: objectively confirmed recurrent VTE occurring during the study period, that means the composite of:

· proximal DVT of the lower limbs (symptomatic or unsuspected), DVT of the upper limb (symptomatic), PE (symptomatic or unsuspected)

Age

18 to 65
65 and over

Gender

N/A

Monetary compensation

No

Can be done from home

No

Keywords

Apixaban, Dalteparin, Pulmonary embolism

Principal Investigator

Martina C Murphy, M.D.

Sponsoring Group

Department of Medicine

Department

Department of Medicine

Contact Information

martina.murphy@medicine.ufl.edu

352.265.8199


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams